Basic Female Viagra Information

• INN (International Nonproprietary Name):

  The term “Female Viagra” generally refers to flibanserin (Addyi) and, less commonly, bremelanotide (Vyleesi), both approved by the FDA for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

• Brand Names Available In United Kingdom:

  Addyi (flibanserin) — marketed in the United States as 100 mg film‑coated tablets; Vyleesi (bremelanotide) — marketed in the United States as a 1.75 mg pre‑filled single‑use autoinjector; other sildenafil‑based products such as Vibasuva F are marketed in countries like India as “female enhancers” but are not approved for HSDD by major regulators.

• ATC Code:

  Flibanserin: G02CX01.

  Bremelanotide: G02CX06.

• Forms & Dosages:

  Flibanserin is supplied as 100 mg oral tablets for once‑daily bedtime dosing.

  Bremelanotide is supplied as a 1.75 mg subcutaneous single‑use autoinjector for as‑needed use before sexual activity.

  Sildenafil generics (sometimes labelled “female Viagra” in other markets) are typically 100 mg oral tablets but are not licensed for female HSDD.

• Manufacturers In United Kingdom:

  Flibanserin (Addyi) is manufactured by Sprout Pharmaceuticals (US) and bremelanotide (Vyleesi) by AMAG Pharmaceuticals (US); no UK manufacturer is listed in the raw data and local supply is typically via import or private clinic sourcing.

• Registration Status In United Kingdom:

  Addyi and Vyleesi are FDA‑approved in the United States for premenopausal, acquired, generalized HSDD.

  Flibanserin was not approved in the EU as of early 2021 and there is no ANMDMR registration reported for Romania as of mid‑2025; UK/MHRA status has limited adoption and routine NHS formularies do not commonly include these agents.

• OTC / Rx Classification:

  Addyi and Vyleesi are prescription‑only medicines in regulated markets.

  Sildenafil generics are sold Rx in many regulated markets and OTC in some countries such as India, but they are not approved for female HSDD by major regulators.

Latest Research Highlights

Worried these drugs will be a game changer overnight?

Recent UK and EU investigations between 2022 and 2025 reinforce what pivotal trials showed: both flibanserin and bremelanotide deliver statistically significant but generally modest improvements in desire measures for premenopausal women with acquired, generalized HSDD.

Systematic reviews from European centres emphasise small effect sizes on validated desire scales and mixed results for patient‑reported satisfaction.

Adverse events are the main reason people stop treatment — dizziness, somnolence and nausea are common with flibanserin, while bremelanotide commonly causes nausea, flushing and injection‑site reactions.

Regulatory summaries underline that Addyi and Vyleesi are FDA‑approved for premenopausal HSDD only, and that EMA/MHRA acceptance has been limited; head‑to‑head comparative trials remain lacking.

UK studies additionally highlight a strong preference for combining drug trials with sex therapy and relationship counselling as part of multi‑modal care.

Clinical Effectiveness In The UK

Will patients notice a clear benefit in everyday practice?

Audits from UK clinics and private practice report modest average improvements: some women report meaningful increases in desire and sexual satisfaction, while many notice only minimal change.

NHS prescribing for HSDD is uncommon and these medicines do not appear on routine NHS formularies due to limited MHRA/EMA adoption and cost‑effectiveness considerations.

Private clinics typically undertake a structured assessment including psychosexual history, mental health review and medication reconciliation before offering pharmacotherapy.

Clinicians in the UK usually recommend a trial of psychological interventions first and then consider drugs for carefully selected patients.

Monitoring checkpoints commonly used are baseline assessment, an 8‑week review for flibanserin, per‑use tolerability checks for bremelanotide and routine adverse event checks documented in clinic notes or NHS electronic records.

Indications And Expanded Uses

Is this medicine right for my situation?

Licensed indications for both flibanserin and bremelanotide are restricted to acquired, generalized HSDD in premenopausal women only, per FDA approvals.

In the UK off‑label use is reported mainly in private settings, for example in postmenopausal women after reversible causes have been addressed or as an adjunct to psychosexual therapy, but evidence for these uses is sparse.

When prescribing off‑label, clinicians should document the clinical rationale, discuss expected benefits and alternatives, and obtain informed consent.

• Licensed: FDA approval for premenopausal, acquired, generalized HSDD.
• Off‑Label: Private use in selected postmenopausal cases or as adjunctive therapy — evidence limited.
• Contraindicated Populations: Pregnancy, breastfeeding, severe hepatic impairment (flibanserin), those taking strong CYP3A4 inhibitors, and patients under 18.

Clinicians are advised to record counselling and consent in patient notes when any off‑label supply is made.

Composition And Brand Landscape In The UK Context

People often ask whether “female Viagra” is actually Viagra for women.

The pharmacology differs substantially: flibanserin is a 5‑HT1A agonist and 5‑HT2A antagonist taken nightly, while bremelanotide is a melanocortin receptor agonist given as a subcutaneous injection before sex.

Sildenafil products marketed as “female Viagra” in some countries are not approved for HSDD and lack robust supporting evidence for female desire disorders.

UK supply channels are typically private clinics, private prescriptions imported or dispensed by registered online pharmacies and specialist clinics rather than routine NHS stock.

Boots, LloydsPharmacy and Superdrug do not commonly stock Addyi or Vyleesi because of limited MHRA/NHS adoption.

Contraindications And Special Precautions

What must be checked before a prescription is issued?

Absolute contraindications include known hypersensitivity to the active ingredient, pregnancy and breastfeeding, and age under 18.

Flibanserin is additionally contraindicated in severe hepatic impairment and with concurrent alcohol because of an increased risk of hypotension and syncope.

Concurrent use of strong CYP3A4 inhibitors is contraindicated with flibanserin due to increased exposure.

Bremelanotide requires caution in patients with cardiovascular disease and those at risk of elevated blood pressure, and dose limits must be observed (no more than eight doses per month).

• Absolute Contraindications: Hypersensitivity, pregnancy, breastfeeding, severe hepatic impairment (flibanserin), concurrent alcohol (flibanserin).
• Relative Precautions: Mild/moderate hepatic or renal impairment, cardiovascular disease, elderly (>65) not studied.

Counselling points for UK patients include warnings about driving or operating machinery if experiencing somnolence or dizziness, strict avoidance of alcohol with flibanserin and careful medicines reconciliation through NHS or pharmacy records.

Dosage Guidelines And NHS‑Relevant Regimens

How are these medicines taken safely in routine care?

Flibanserin dosing is 100 mg orally once nightly at bedtime on a continuous basis, with reassessment at about eight weeks to judge benefit and tolerability.

Bremelanotide dosing is 1.75 mg by subcutaneous injection at least 45 minutes before sexual activity, with a maximum of one dose in 24 hours and eight doses per month.

NHS practice stresses documented baseline assessment, shared decision‑making and safety monitoring, including blood pressure checks where clinically indicated and liver function consideration for flibanserin.

Initiation checklist used in UK settings: screen for HSDD, review medications and mental health, counsel on contraindications (alcohol, liver disease), record consent, baseline BP if indicated and plan an 8‑week review for flibanserin.

Interactions Overview (Food, Drink, Drugs)

What interactions most often cause harm?

Flibanserin has clinically important interactions with alcohol and strong CYP3A4 inhibitors; combined use with alcohol is contraindicated because of severe hypotension and syncope risk.

Strong CYP3A4 inhibitors increase flibanserin exposure and are contraindicated in the product literature.

Concurrent CNS depressants such as opioids or benzodiazepines may potentiate somnolence with flibanserin and should prompt caution.

Bremelanotide can affect blood pressure, so co‑use with sympathomimetics or other BP‑raising agents should be cautious and monitored.

Pharmacists should flag interactions on EPS and advise patients clearly, particularly about alcohol and CYP3A4 inhibitors for flibanserin.

Cultural Perceptions And Patient Habits In The UK

How do people in the UK actually talk about low desire?

Online forums such as Patient.info and Mumsnet commonly show strong interest in non‑drug approaches and a tendency to discuss natural remedies and supplements alongside medical options.

Stigma remains a barrier for some patients in primary care, and many prefer private clinics or online consultations for perceived confidentiality when seeking help for sexual desire issues.

Community pharmacists are expected to provide accessible first‑line advice and to flag red‑flag symptoms for GP or specialist referral.

• Common Patient Attitudes: Preference for therapy and relationship work, curiosity about “female Viagra” and supplements.
• Help‑Seeking Behaviour: Many contact pharmacists or NHS 111 before visiting a GP; some use private clinics for confidentiality.

Trusted UK information sources include NHS patient leaflets, specialist sexual health services and accredited psychosexual therapists listed via professional bodies.

Availability And Pricing Patterns In The UK

How easy is it to get these treatments and how much will they cost?

Addyi and Vyleesi are prescription‑only and not routinely stocked by major UK pharmacy chains because of limited MHRA and NHS adoption; private providers commonly source products under private prescription or import arrangements.

Pricing varies in private settings and clinics; these medicines are not generally supplied on the NHS, so patients usually pay privately where available.

In our online pharmacy, female viagra is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Patients should verify supplier legitimacy by checking MHRA registration, pharmacy credentials and that a valid prescription is required for private supply where appropriate.

• Common Access Routes: Private clinic supply, private prescription/import, registered online pharmacy.
• Safety Tip: Avoid unregulated overseas suppliers offering sildenafil‑labelled “female Viagra” tablets without proper prescription checks.

Comparable Medicines And Prescribing Preferences

What else might a clinician choose instead?

UK clinicians often favour a multi‑modal approach: address reversible causes, consider hormone treatments for menopausal changes (such as topical oestrogens), switch culpable antidepressants where feasible and offer psychological therapies including CBT and sex therapy.

PDE5 inhibitors such as sildenafil are sometimes marketed as “female Viagra” in other countries but they lack major regulatory approval for female HSDD and are not standard NHS options for desire disorders.

• Addyi: Nightly oral option with central serotonergic action — modest benefit, alcohol contraindications.
• Vyleesi: As‑needed injectable option — useful for situational dosing but may cause nausea and BP effects.
• Non‑Drug Options: Sex therapy, relationship counselling, lifestyle and medical optimisation are core elements.

Clinician preference usually places pharmacotherapy after psychological assessment and targeted treatment of underlying medical or psychiatric contributors.

FAQ

Can I get “female Viagra” on the NHS?

Currently these agents are not routinely prescribed on the NHS; access is usually via private prescription or specialist clinics and influenced by MHRA/EMA regulatory positions.

Is it safe to drink alcohol while taking Addyi?

No — concurrent alcohol is contraindicated with flibanserin because of the risk of severe hypotension and syncope; strict counselling and abstinence guidance are required.

Will it work for my low libido?

Response is variable; some patients report meaningful benefit while others notice little change — average effect sizes are modest and combining drugs with psychological approaches is often recommended.

Are online “female Viagra” tablets safe?

Many online products labelled as “female Viagra” are unregulated sildenafil tablets from overseas and are not licensed for women; verify pharmacy registration and avoid unverified suppliers.

Guidelines For Proper Use And Pharmacist Counselling Style

What should a pharmacist cover in a consultation?

Confirm the indication is acquired, generalized HSDD and that reversible causes have been reviewed.

Review the full medication history with attention to CYP3A4 inhibitors and CNS depressants and screen for depression and relationship issues that may explain low desire.

Explain dosing and timing clearly: flibanserin is nightly, bremelanotide is pre‑sex, and emphasise safety messages such as no alcohol with flibanserin and blood pressure checks for bremelanotide as needed.

1. Step 1: Screen — psychosexual history, mental health and medication review.
2. Step 2: Counsel — dosing, side effects, alcohol/CYP3A4 cautions and driving warnings.
3. Step 3: Document — record consent and advice in NHS electronic records or private clinic notes.
4. Step 4: Follow‑Up — 8‑week review for Addyi, per‑use tolerability check for Vyleesi, and Yellow Card reporting for adverse events.

Provide printed or portal leaflets, offer referral to psychosexual therapy and advise on licensed alternatives and lifestyle measures as part of shared decision‑making.

Delivery Across United Kingdom